Inflammatory bowel disease (IBD) has become a global disease. As IBD is a chronic disease that can result in remarkable morbidity and disability, estimation and understanding the disease burden of IBD is imperative to prepare adequate health care systems. However, variations in IBD incidence or prevalence may reflect differences in the distribution, and there are regional disparities in Asia with a large population of approximately 4.6 billion in 2020, which is equivalent to 60% of the total world population. Although comprehensive understanding of the epidemiology of IBD in Asian countries is difficult, this review includes updated data regarding the incidence and prevalence of IBD and the estimated disease burden in Asia. (Intest Res 2022;20:159-164)

Key Words: Inflammatory bowel disease; Epidemiology; Asia
In a population-based inception cohort from Songpa-Kangdong district, Korea was updated with a 30-year study period from 1986 to 2015. The age- and sex-adjusted annual incidence of IBD has increased continuously throughout the 30-year period: from 0 in 1986 to 2.42/100,000 inhabitants in 2015 for CD and from 0.33/100,000 inhabitants in 1986 to 6.58/100,000 inhabitants in 2015 for UC. According to this study, CD incidence had increased approximately 40 times during the past three decades, and UC incidence had increased approximately 20 times. The average annual percentage change (APC) in IBD incidence was 12.3% during 1986–1995 and 12.3% during 1996–2005, whereas it was only 3.3% during 2006–2015 (P < 0.05). This indicates a moderation in the increase in IBD incidence in recent years, despite the continued increase in the incidence of IBD. Recently, the incidence and prevalence data from Korea using a nationwide health insurance database reported conflicting results. Two studies reported a plateau or even decrease in the IBD incidence in Korea between 2006 and 2014. One of the studies reported CD and UC incidences as 3.6/100,000 and 5.0/100,000, respectively, in 2006 and 3.1/100,000 and 4.2/100,000, respectively, in 2012. The other study reported the incidences of CD and UC as 3.1/100,000 and 5.9/100,000, respectively, in 2011 and 2.4/100,000 and 5.0/100,000, respectively, in 2014. However, the most recent study using this database reported of increased IBD incidence between 2009 and 2016. This study reported the incidences of CD and UC as 2.4/100,000 and 4.0/100,000, respectively, in 2009 and 2.9/100,000 and 4.0/100,000, respectively, in 2016. This discrepancy could be because of the difference in the definition of incident cases and relatively short washout periods between the enrollment in the administrative database and IBD diagnosis, which can cause a misclassification between the incident and prevalent cases. A similar discrepancy was observed for North America in which the incidence of IBD decreased between 1996 and 2009 in the Canadian population-based study. Cases may have been underestimated because IBD diagnosis was not based on clinical diagnosis and medical record review, but on a diagnostic code-based scoring systems including the International Classification of Diseases-9 codes, physician billing claims, and discharge diagnoses.

In 2019, longitudinal data on the incidence of IBD were reported in Taiwan. A retrospective analysis was performed using data, between January 2001 and December 2015, from the National Health Insurance and the Ministry of Health and Welfare, Taiwan. The crude incidence of CD increased from 0.17/100,000 in 2001 to 0.47/100,000 in 2015, and the crude incidence of UC increased from 0.54/100,000 in 2001 to 0.95/100,000 in 2015. The APC was 2.69 by the joinpoint trend analysis for the general trends in patients diagnosed with IBD, which was significant from 2001 to 2015. The trend of CD also increased significantly according to the joinpoint trend analysis from 2001 to 2015, with the APCs as 4.75 (2001–2010) and 15.92 (2010–2015), whereas they were nonsignificant in the trend for UC, given that the APC value was 0.82 from 2001 to 2015.

According to the multinational epidemiological study from Asia, the Asia-Pacific Crohn’s and Colitis Epidemiologic Study (ACCESS), the incidence of IBD had an increasing trend in Asian countries including Brunei, China, Hong Kong, India, Indonesia, Macau, Malaysia, Singapore, Sri Lanka, Taiwan, Thailand, and the Philippines. Between 2011 and 2013, the mean annual crude incidence of IBD per 100,000 in Asia was 1.50 (95% confidence interval [CI], 1.43–1.57). From 2011 to 2012, the crude overall annual incidence per 100,000 of IBD, CD, and UC in Asia was 1.14 (95% CI, 1.06–1.23), 0.35 (95% CI, 0.31–0.40), and 0.76 (95% CI, 0.69–0.84), respectively. From 2012 to 2013, and the corresponding incidence rates were 1.89 (95% CI, 1.77–2.01), 0.66 (95% CI, 0.60–0.73), and 1.20 (95% CI, 1.11–1.29), respectively.

In a multicenter study using a hospital and territory-wide administrative coding system from Hong Kong, the age-adjust-
ed incidence of IBD per 100,000 individuals increased from 0.10 (95% CI, 0.06–0.16) in 1985 to 3.12 (95% CI, 2.88–3.38) in 2014. The age-adjusted incidence per 100,000 increased from 0.01 (95% CI, 0.00–0.03) in 1985 to 1.46 (95% CI, 1.29–1.65) in 2014 for CD and from 0.09 (95% CI, 0.05–0.15) in 1985 to 1.51 (95% CI, 1.35–1.69) in 2014 for UC.

In Japan, recent data on the longitudinal analysis of IBD epidemiology have been lacking. However, we have observed a constant increase in the incidence of IBD over the past 60 years, as published in the previous reports. In 1955, the incidence of CD and UC was 0.002/100,000 and 0.03/100,000, respectively. In 1991, the incidence of CD and UC had risen to 0.51/100,000 and 1.95/100,000, respectively. In 1986 to 1998, the CD incidence has been estimated to be as high as 0.9/100,000. A recent report using a survey conducted in 2014 reported the incidence of CD as 2.0/100,000 and the incidence of UC as 12.2/100,000.

In China, longitudinal data on the trend in the incidence of IBD is not available. In meta-analyses that summarized the epidemiologic data on a national level, the incidence of CD was estimated at 0.28/100,000 during 1950–2002 and this was slightly increased to 0.85/100,000 on extending the period to 1950–2007 in mainland China. A population-based study from Wuhan reported the age-adjusted incidence of IBD, CD, and UC in China were 1.61, 0.34, and 1.21, respectively, between 2011 and 2013. In addition, within China, the pooled incidence of IBD varied from 0.18/100,000 to 0.73/100,000 for CD and 1.12/100,000 to 1.33/100,000 for UC according to the population density of the regions.

In Southeast Asia and South Asia, only a few studies on the epidemiology or natural course of IBD have been published, most of which are referral-center-based studies. Based on the data from the ACCESS, the pooled incidence of UC was lower in Southeast Asia than that in East Asia (0.49/100,000 vs. 1.14/100,000; P = 0.002) and the pooled incidence of CD was comparable between Southeast Asia and East Asia (0.36/100,000 vs. 0.34/100,000; P = 0.878).

2. Prevalence and Estimated Number of Patients with IBD

Table 1 lists the recent prevalence data from the Asian countries.

<table>
<thead>
<tr>
<th>Country</th>
<th>Year of incidence data</th>
<th>IBD incidence (/10^5)</th>
<th>Year of prevalence data</th>
<th>IBD prevalence (/10^5)</th>
<th>Population (million)</th>
<th>No. of patients with IBD</th>
<th>Percentage of the population</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Korea</td>
<td>2015</td>
<td>9.0</td>
<td>2015</td>
<td>108.4</td>
<td>51.5</td>
<td>55,800</td>
<td>0.11</td>
</tr>
<tr>
<td>Japan</td>
<td>2014</td>
<td>14.2</td>
<td>2014</td>
<td>165.1</td>
<td>127.3</td>
<td>210,200</td>
<td>0.17</td>
</tr>
<tr>
<td>Taiwan</td>
<td>2015</td>
<td>1.4</td>
<td>2015</td>
<td>16.7</td>
<td>23.5</td>
<td>3,900</td>
<td>0.02</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>2014</td>
<td>3.0</td>
<td>2014</td>
<td>44.0</td>
<td>7.2</td>
<td>3,200</td>
<td>0.04</td>
</tr>
<tr>
<td>Malaysia</td>
<td>2011–2013</td>
<td>0.7</td>
<td>2011–2013</td>
<td>9.2</td>
<td>29.5</td>
<td>2,700</td>
<td>0.01</td>
</tr>
<tr>
<td>China</td>
<td>2011–2013</td>
<td>1.6</td>
<td>2007</td>
<td>2.3^a</td>
<td>1,318</td>
<td>30,300</td>
<td>0.00</td>
</tr>
<tr>
<td>India</td>
<td>2012–2013</td>
<td>9.3</td>
<td>2000</td>
<td>44.3^a</td>
<td>1,057</td>
<td>468,300</td>
<td>0.04</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>NA</td>
<td>2017</td>
<td>113.9</td>
<td>18.0</td>
<td>20,500</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>2000–2010</td>
<td>22.9</td>
<td>2010</td>
<td>530</td>
<td>309</td>
<td>1,637,700</td>
<td>0.53</td>
</tr>
<tr>
<td>Sweden</td>
<td>2010</td>
<td>40.0</td>
<td>2010</td>
<td>540</td>
<td>9.9</td>
<td>55,100</td>
<td>0.54</td>
</tr>
<tr>
<td>Switzerland</td>
<td>NA</td>
<td>2014</td>
<td>408</td>
<td>8.4</td>
<td>34,300</td>
<td>0.41</td>
<td></td>
</tr>
</tbody>
</table>

^aOnly Crohn’s disease data available.
^bOnly ulcerative colitis data available.
IBD, inflammatory bowel disease; NA, not available.
tries. We calculated the actual number of patients with IBD to estimate the real disease burden of IBD in this region. Census data from each country were used to estimate the national population for the years of the prevalence study. Available data on prevalence were superimposed on the national population at the time of the study to estimate the disease burden of CD or UC. In Korea and Japan, approximately 0.1%–0.2% of the general population may have IBD.3,19 This range is lower than that in the Western regions such as the United States, affecting up to 0.5% of the general population.31,32,34 Taiwan, Hong Kong, and Malaysia have a lower IBD disease burden than that of Korea and Japan.13,15,26 Although no recent prevalence data have been reported in China and India, which have a huge population of more than 1 billion people, these countries might have substantially higher numbers of patients with IBD compared with Western countries.35 In Central Asia, one recent report on the prevalence of IBD in Kazakhstan showed that the prevalence of IBD, CD, and UC were 113.9/100,000, 29.5/100,000, 84.4/100,000 without incidence data.30 However, these figures are much higher than that reported by the Ministry of Health of Kazakhstan (31.5/100,000 for UC and 6.3/100,000 for CD), perhaps because of the heterogeneity of study designs.36

DISCUSSION

Kaplan and Windsor37 had recently suggested that the evolution of IBD epidemiology can be stratified into 4 epidemiological stages: emergence (sporadic incident cases with IBD begin to emerge in a population), acceleration in incidence (a dramatic increase in the number of incident cases with IBD is observed, but overall prevalence remains low), compounding prevalence (incidence rates of IBD stabilize or even decline, but the slope of prevalence of IBD continues to accelerate owing to decades of high incidence with low mortality), and prevalence equilibrium (the slope of prevalence of IBD begins to level off owing to stable incidence of IBD and an aging prevalent population with higher mortality). Based on this stratification, most Asian countries experiencing a rising incidence with a low prevalence of IBD are embedded in the second epidemiological stage (acceleration in incidence). Considering the huge population in Asian countries, including China and India, Asia alone might have a greater disease burden with IBD than that of the Western world in the near future. One modeling study from Iran expected a 1.5-fold increase in prevalence for East Asia with 4.5 million cases of IBD and quadrupling of the prevalence for India with 2.2 million cases of IBD in 2035, as compared to 2020.38 However, data should be interpreted with caution given the vast heterogeneity between the reported incidence rates among the Asian countries and regions within these countries, such as data of the ACCESS.4,30,36,37 Asian countries are currently in various stages according to the industrialization status. For example, Korea and Japan have experienced more rapid industrialization than the other Asian countries and transitioned into the second stage earlier than the other Asian countries. Therefore, these countries may enter the compounding prevalence stage (stage 3) with a rapid increase in the prevalence of IBD after several decades of accelerated incidence (stage 2), similar to the experience in Western countries in the 21st century. In conclusion, considering the current status of rapidly rising incidence and the subsequent explosive increase in the prevalence of IBD in Asia, the healthcare delivery systems, including the resource setting, should be prepared for this challenge by understanding the exact disease burden of IBD in this region.

ADDITIONAL INFORMATION

Funding Source
The author received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Author Contribution
Writing and approval of final manuscript: Park SH.

ORCID
Park SH https://orcid.org/0000-0002-5366-5749

REFERENCES

30. Kaibullayeva J, Ualiyeva A, Oshibayeva A, Dushpanova A, Mar-


